omeprazole has been researched along with diazepam in 42 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (9.52) | 18.7374 |
1990's | 14 (33.33) | 18.2507 |
2000's | 13 (30.95) | 29.6817 |
2010's | 10 (23.81) | 24.3611 |
2020's | 1 (2.38) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Flouvat, B; Karolac-Tamisier, S; Lefebvre, RA; Moerman, E; Van Ganse, E | 1 |
Humphries, TJ | 1 |
Andersson, T; Cederberg, C; Edvardsson, G; Heggelund, A; Lundborg, P | 1 |
Brand, U; Gönne, S; Hanauer, G; Kromer, W; Parsons, ME; Postius, S; Riedel, R; Simon, WA | 1 |
Andersson, T; Andrén, K; Cederberg, C; Edvardsson, G; Heggelund, A; Lundborg, P | 1 |
Ayrton, A; Chenery, RJ; Norman, SJ; Oldham, HG; Standring, P | 1 |
Regårdh, CG | 1 |
Gugler, R; Jensen, JC | 2 |
Caraco, Y; Tateishi, T; Wood, AJ | 1 |
Chiba, K; Hayashi, M; Horai, Y; Ishizaki, T; Koyama, E; Manabe, K; Tomono, Y; Toyoki, T; Yamato, C; Yasuda, S | 1 |
Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K | 1 |
Bertilsson, L | 1 |
Houston, JB; Zomorodi, K | 3 |
Bliesath, H; Brod, I; Gugler, R; Hartmann, M; Huber, R; Klotz, U; Rudi, J; Steinijans, VW; Wurst, W | 1 |
Fask, A; Saltiel, E | 1 |
Adler, ID; Baumgartner, A; Schmid, TE | 1 |
Sontag, SJ | 1 |
Bertino, JS; Nafziger, AN; Rogers, JF | 1 |
Hallifax, D; Houston, JB; Jones, HM | 1 |
Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F | 1 |
Coleman, HM; Khan, SJ; Le-Clech, P; Stuetz, RM; Trinh, T; van den Akker, B | 1 |
d'Auriol, M; de Souza Santos, LV; Jacob, RS; Lange, LC; Lebron, YAR; Moreira, VR | 1 |
6 review(s) available for omeprazole and diazepam
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole.
Topics: Aminopyrine; Animals; Antipyrine; Cytochrome P-450 Enzyme System; Diazepam; Drug Interactions; Humans; Omeprazole; Phenytoin; Propranolol; Theophylline; Warfarin | 1991 |
Lack of pantoprazole drug interactions in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin | 1994 |
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Topics: Antidepressive Agents; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Diazepam; Geography; Humans; Mixed Function Oxygenases; Mutation; Omeprazole; Pharmaceutical Preparations; Phenotype; Polymorphism, Genetic; Racial Groups; Substrate Specificity; White People | 1995 |
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Topics: Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Codeine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Diazepam; Genotype; Glipizide; Humans; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Phenotype; Phenytoin; Warfarin | 2002 |
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induced Liver Injury; Darbepoetin alfa; Diazepam; Erythropoietin; Fatal Outcome; Humans; Jaundice, Obstructive; Liver Function Tests; Male; Melphalan; Multiple Myeloma; Omeprazole; Pneumonia; Polypharmacy; Prednisolone; Thalidomide | 2012 |
7 trial(s) available for omeprazole and diazepam
Article | Year |
---|---|
Influence of lansoprazole treatment on diazepam plasma concentrations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Anti-Ulcer Agents; Diazepam; Double-Blind Method; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Reference Values | 1992 |
Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.
Topics: Adult; Diazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Humans; Male; Metabolic Clearance Rate; Nordazepam; Omeprazole; Random Allocation | 1990 |
Effect of omeprazole and cimetidine on plasma diazepam levels.
Topics: Adult; Cimetidine; Diazepam; Double-Blind Method; Drug Interactions; Half-Life; Humans; Male; Nordazepam; Omeprazole | 1990 |
Interethnic difference in omeprazole's inhibition of diazepam metabolism.
Topics: Adult; Asian People; China; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Diazepam; Double-Blind Method; Drug Interactions; Ethnicity; Humans; Male; Mephenytoin; Nordazepam; Omeprazole; Tennessee; White People | 1995 |
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Diazepam; Drug Interactions; Half-Life; Humans; Hydroxylation; Male; Mephenytoin; Mixed Function Oxygenases; Nordazepam; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Reference Values; Single-Blind Method | 1995 |
Lack of pantoprazole drug interactions in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin | 1994 |
Lack of pharmacokinetic interaction of pantoprazole with diazepam in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Blood Pressure; Cross-Over Studies; Diazepam; Drug Interactions; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Omeprazole; Pantoprazole; Sulfoxides | 1996 |
30 other study(ies) available for omeprazole and diazepam
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Diazepam; Female; Gastric Acid; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Motor Activity; Omeprazole; Pantoprazole; Rabbits; Rats; Rats, Inbred Strains; Sulfoxides | 1990 |
The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo.
Topics: 7-Alkoxycoumarin O-Dealkylase; Animals; Cimetidine; Diazepam; Ethylmorphine-N-Demethylase; In Vitro Techniques; Male; Microsomes, Liver; NADPH-Ferrihemoprotein Reductase; Omeprazole; Oxidoreductases; Oxygenases; Rats; Rats, Inbred Strains; Species Specificity | 1988 |
Pharmacokinetics and metabolism of omeprazole in man.
Topics: Administration, Oral; Aged; Aging; Anti-Ulcer Agents; Benzimidazoles; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Humans; Injections, Intravenous; Kidney Diseases; Kinetics; Omeprazole | 1986 |
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.
Topics: Adult; Benzimidazoles; Coumarins; Diazepam; Drug Interactions; Humans; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Nordazepam; Omeprazole; Oxidation-Reduction; Phenytoin | 1985 |
Omeprazole inhibits elimination of diazepam.
Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Diazepam; Drug Interactions; Humans; Male; Metabolic Clearance Rate; Omeprazole | 1984 |
Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies.
Topics: Animals; Anti-Anxiety Agents; Anti-Ulcer Agents; Biotransformation; Chromatography, High Pressure Liquid; Diazepam; Drug Interactions; In Vitro Techniques; Liver; Male; Microsomes, Liver; Omeprazole; Rats; Rats, Sprague-Dawley; Tissue Distribution | 1995 |
Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes.
Topics: Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Diazepam; Drug Interactions; Female; Humans; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Omeprazole | 1996 |
Selectivity of omeprazole inhibition towards rat liver cytochromes P450.
Topics: 7-Alkoxycoumarin O-Dealkylase; Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diazepam; Ethylmorphine-N-Demethylase; Ketoconazole; Male; Microsomes, Liver; Omeprazole; Rats; Rats, Sprague-Dawley; Substrate Specificity | 1997 |
Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diazepam; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pharmacies; Prevalence; Proton Pump Inhibitors; Retrospective Studies; Theophylline; Warfarin | 1999 |
Induction of aneuploidy in male mouse germ cells detected by the sperm-FISH assay: a review of the present data base.
Topics: Acrylamide; Aneuploidy; Animals; Benzimidazoles; Carbamates; Colchicine; Diazepam; Griseofulvin; Humans; In Situ Hybridization, Fluorescence; Male; Meiosis; Mice; Mice, Inbred C3H; Omeprazole; Paclitaxel; Spermatozoa; Substance-Related Disorders; Thiabendazole; Trichlorfon; Vinblastine | 2002 |
Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy.
Topics: Adult; Aged; Diazepam; Drug Therapy, Combination; Enzyme Inhibitors; Follow-Up Studies; Gastroesophageal Reflux; Humans; Hypnotics and Sedatives; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes.
Topics: Animals; Binding Sites; Diazepam; Dose-Response Relationship, Drug; Hepatocytes; Kinetics; Male; Metabolic Clearance Rate; Microsomes, Liver; Omeprazole; Predictive Value of Tests; Rats; Rats, Sprague-Dawley | 2004 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Removal of trace organic chemical contaminants by a membrane bioreactor.
Topics: Amitriptyline; Bioreactors; Carbamazepine; Diazepam; Diclofenac; Fluoxetine; Gemfibrozil; Omeprazole; Organic Chemicals; Pharmaceutical Preparations; Sulfamethoxazole; Trimethoprim; Waste Disposal, Fluid; Water Pollutants, Chemical | 2012 |
Diazepam, metformin, omeprazole and simvastatin: a full discussion of individual and mixture acute toxicity.
Topics: Aliivibrio fischeri; Diazepam; Metformin; Omeprazole; Simvastatin; Toxicity Tests, Acute | 2020 |